Ixiaro: supply restrictions…

Ixiaro: supply restrictions…

Medicines and Healthcare Products Safety Agency reported on February 12, 2024. hospital channel supply limitation regarding the Ixiaro vaccine (Valnev laboratory). This vaccine is indicated for active immunization against Japanese encephalitis in adults, adolescents, children and infants over 2 months of age. The use of Ixiaro should be considered in persons at risk of contracting the virus during travel or in the context of their professional activities.

  • Closure of the city canal
  • Hospital channel quota.
  • Emergency stock for vaccination centers, hospitals and pharmacies
  • Regular delivery is scheduled for the end of March 2024.

In this regard, the Valnev laboratory has issued the following recommendations:

  • Give priority to vaccinating people who have already started their primary vaccination schedule,
  • Delay the start of the new primary vaccination schedule for patients traveling after April 2024.
  • If necessary, delay booster doses.

In situations where the primary vaccination schedule has already begun (the patient is awaiting the second injection), an emergency stock is created to be able to supply the centers with vaccine.
international vaccinations and community pharmacies.

Health workers are being asked to redirect patients awaiting their second injection to one of the international vaccination centres.

For any request that meets the stated criteria, you can contact the CSP depository directly at Commande_adv@movianto.com, indicating the order context (1st injection date, departure date).

In order to maximize the safety of the situation in France and preserve existing stocks, the sale and export of the drug by wholesale distributors abroad is prohibited, and the publication of this information sheet on the website of the National Agency for the Safety of Medicines is prohibited. and health products (ANSM) in accordance with the Public Health Law 2016-41, published in the Official Journal on January 27, 2016, and the provisions of articles L.5121-30 and L.5124-17-3 of the Public Health Code. This measure, which prohibits sales outside the national territory or to wholesale distributors for export, must be applied and respected until the medicine becomes routinely available to ensure a continuous and adequate supply to the national market.

Source: National Agency for Medicines and Health Products (ANSM).

Hi, I’m laayouni2023